Synergizing Proteolysis-Targeting Chimeras and Nanoscale Exosome-Based Delivery Mechanisms for HIV and Antiviral Therapeutics

Abstract

The global fight against Human Immunodeficiency Virus (HIV) and related viral infections stands at a pivotal juncture, demanding groundbreaking therapeutic strategies. Facing the challenges of existing antiviral treatments, such as viral resistance and nonspecific actions, this paper unveils a transformative approach. We introduce an innovative synergy between proteolysis-targeting chimeras (PROTACs) and exosome-based delivery mechanisms, heralding an innovative era in combating HIV and similar viral diseases. PROTACs emerge as a trailblazing solution, strategically targeting and decomposing crucial viral proteins, and thus, obstructing viral replication and diminishing pathogenesis. Complementing this, the use of exosome-based delivery systems─nature’s own nanoscale couriers─ensures the precise and effective transportation of these dynamic chimeras directly to infected cells and viral reservoirs. This synergistic strategy is not just a leap forward in HIV therapy; it represents a paradigm shift in antiviral interventions at large. The path to realizing the full potential of these avant-garde technologies lies in sustained research investments, cross-disciplinary collaborations, and rigorous safety and efficacy trials. By channeling these efforts toward HIV, a cornerstone in global health research, we are not just envisioning but actively forging path-breaking advancements in antiviral therapeutics. This represents more than scientific progress; it is a beacon of hope, promising to significantly uplift the lives of those battling these formidable diseases.